Historically, TB Alliance has prioritized developing therapies that are deliverable orally. The organization is now also exploring the use of long-acting injectable therapies, especially for the treatment of latent TB. This strategic evolution reflects a desire to make treatment more effective and easier for those administering and receiving it. This preclinical program will begin studing LAIs in four drugs: pretomanid, TBAJ-876, TBAJ-587, and Q-203.